Valneva begins COVID-19 vaccine production

By The Science Advisory Board staff writers

Valneva has begun production of its inactivated COVID-19 vaccine candidate in conjunction with ongoing clinical studies from which the company expects to report results in April.

In September, Valneva signed a partnership with the U.K. government to supply up to 190 million doses of VLA2001, which consists of inactivated SARS-CoV-2 virus particles with high S-protein density combined with two adjuvants: alum and CpG 1018. It is the only inactivated vaccine candidate in clinical trials in Europe, according to Valneva. If the vaccine is developed successfully, Valneva will supply the U.K. government with 60 million doses in the second half of this year.

Phase I/II of the study began in December 2020 and includes 150 healthy adults. It will evaluate three dose levels of the vaccine for safety, tolerability, and immunogenicity in a two-dose schedule three weeks apart, Valneva said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?